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ABSTRACT 
Multiple Myeloma (MM) is the second most common hematologic malignancy. Despite 
the advancements in treatment approaches in the last decade, the prevalence of 
refractory disease leading to relapsed cases has been a major challenge. A wide range 
of intricate genetic heterogeneity demonstrated by myeloma patients is a credible 
explanation for the diverse treatment responses observed in patients sharing the same 
treatment regimens. Pertaining to this, the study aims to identify predictive gene 
expression biomarkers that forecast response to BCL2 inhibitor venetoclax and 
treatment outcome to proteasome inhibitor bortezomib. In this study, samples from MM 
patients were characterized into sensitive and resistant, (1) based on ex vivo response 
to venetoclax treatment (Resistant n=21; Sensitive n=21), and (2) based on their 
bortezomib treatment outcome in clinical profiles (Resistant n=12; Sensitive n=15). 
Associations between the different gene expressions and drug responses were studied 
using statistical and bioinformatic tools. As a result, we identified that significant (p-
value <0.05) overexpression of 36 genes and downregulation of 38 genes appeared to 
confer resistance to venetoclax drug response in MM patients. Additionally, the 
functional association of these genes with pathways was determined using a pathway 
enrichment tool. Furthermore, the study provided evidence that cytogenetic alterations 
t(11;14) and t(4;14) are significantly (p-value <0.05) associated with differing 
venetoclax response in MM patients. These findings demonstrated that gene expression 
biomarkers and chromosomal translocations play a significant role in regulating 
venetoclax drug response in MM, which can be further utilized to personalize 
treatments for patients. The knowledge obtained from this work best applies in 
personalized medicine; whereby fitting treatments to an individual patient’s genomic 
landscape will enhance patient outcome. 
 
Keywords: Multiple Myeloma, Biomarkers, Venetoclax, Bortezomib, Bioinformatics, 
Personalized Medicine 
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1. INTRODUCTION 
 
According to the latest fact sheet by the World Health Organization (WHO), new cancer 
cases have risen to approximately 18.1 million and cancer has taken the lives of 9.6 
million people in 2018. There has been a huge reduction in the overall mortality rate of 
cancer patients in the last 20 years 1. This dramatic improvement can be attributed to 
new treatment strategies, especially immunotherapy and targeted treatment approaches. 
However, a major issue in cancer treatment (especially in hematologic malignancies) 
remains the emergence of refractory disease which ultimately leads to reduced life 
expectancies 2. The higher number of relapsed cases caused due to drug resistance, 
impose a serious clinical and economic burden, globally. The fact that this burden 
remains while newer strategies for treatments are developing, points to a gap between 
the expanding knowledge from cancer research and the translational ability of this 
information in the clinical setting.  
A series of complex mechanisms and increased disease heterogeneity of cancer makes 
it difficult for one-size-fits-all kind of treatment approach to work effectively. The 
innate variability of treatment responses in different patients paves the way for 
personalized medicine. It is a promising approach according to which medical 
treatments are tailored based on distinct patient characteristics. Personalized medicine 
can be applied best in the context of analyzing genetic variation in patients to predict 
better prognosis, diagnosis, or treatment for individual patients. However, the 
successful clinical application of this approach depends on the availability of pre-
existing validated knowledge about markers that can indicate those genetic variations.  
Thus, in this study, we attempt to identify predictive biomarkers that can indicate 
resistant or sensitive responses to venetoclax and bortezomib treatments in Multiple 
Myeloma (MM). With this approach, in future, individual MM patients can be stratified 
into different treatment subsets based on their predictive responses. These stratifications 
will help to minimize disease relapse. Therefore, it is increasingly imperative for current 
and upcoming MM research to investigate the role of genetic data in patient care, to 
bring about individually tailored treatment approaches. This has the potential to 
alleviate the relapse burden in MM and improve the overall patient outcome. 
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2. LITERATURE REVIEW 
 
2.1 Overview of Hematologic Malignancies 
Hematopoiesis is a tightly regulated process of blood cell formation and development 
in which multipotent hematopoietic stem cells (HSCs) differentiate into mature blood 
cells with specific fixed functions to perform in the human body 3. The adult 
hematologic system is comprised of about 10 types of blood cells that can be broadly 
classified into leukocytes (White Blood Cells (WBCs)) that are responsible for the 
human immune response, erythrocytes (Red Blood Cells (RBCs)) that transport oxygen 
and carbon dioxide and thrombocytes (Platelets) that are responsible for blood clotting. 
The system that houses the process of hematopoiesis in adults includes bone marrow, 
liver, spleen, and other lymphatic tissues. Intricate gene expression coordination strictly 
regulated by multitude transcription factors is what shapes the fate of HSCs to produce 
mature progeny 4.   
Hematologic malignancies are a broad range of neoplastic transformations that affect 
different blood cell types and at different levels of their development. Disruptions in 
the genetic regulation of hematopoiesis at different points cause different types of 
malignancies 4. Altogether these malignancies can be broadly classified into lymphoid 
malignancies, effecting the cells of lymphoid lineage, and myeloid malignancies, 
occurring in cells of myeloid lineage 5. According to a combination of lineage, 
morphology, immunophenotype, genetic and clinical features, the World Health 
Organization (WHO) presented an updated classification of hematologic neoplasms in 
2008 that classifies them into around 60 subtypes 5,6 (Figure 1).  Hematopoietic 
neoplasms account for being the sixth most common group of cancer malignancies in 
the world and are more often occurring in the male population compared to females 7. 
There exists a wide range of etiological diversity between the different subtypes of 
hematologic neoplasms, thus there is a poor understanding of the causative factors 
contributing to hematologic malignancies 8. In this study, we will be focusing on Plasma 
B Cell malignancy: Multiple Myeloma. 
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2.2 Plasma Cells 
Plasma B cells originate in the secondary lymphoid organs (e.g. lymph nodes) from 
differentiated antigen-activated B cells and soon after their formation they travel and 
inhabit the bone marrow 9. They are a major element of humoral immunity because of 
their ability  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Classification of Hematologic Neoplasms. 
Adapted from Severson, C. (2016)
4 
 
to produce high quantities of antibodies and because of their extended life period 10. 
Terminally differentiated plasma cells undergo loss of surface markers that are 
otherwise quite common in B cells, like CD19 and CD20, which makes them difficult 
to identify 11. Mature plasma cells express high levels of CD-138 (syndecan-1) and 
CD38 11, while CD54 and CD319 are good indicators of human plasma cells 12, 13. 
 
2.2.1 Plasma Cell Development  
When immature B cells encounter antigens in secondary lymphoid tissues, they can 
differentiate into memory B cells or plasma cells 9. Interactions between antigen 
specific helper T cell and B cell cause the activation, proliferation, and differentiation 
of B cells 12. In the secondary lymphoid organs, there are two possible fates for the 
activated B-cells, (1) extra-follicular activated B-cells differentiate into low-affinity 
antibody-secreting short term plasma cells that remain in the secondary lymphoid tissue 
(they have less significance in malignancies) (2) Germinal Center (GC) activated B-
cells differentiate into long-lived plasma cells that are located in the bone marrow and 
secrete high affinity antibodies 14. Activated B cells along with helper T cells and 
dendritic cells together form the germinal center (GC) in the secondary lymphoid 
tissues 15,12. Following activation in the GC, B-cells undergo somatic hypermutations 
(SHM) in the genes that are responsible for the Variable region of the B cell receptors 
(BCR) 16. These genes are responsible for the binding specificity of the BCR, thus 
SHMs causing accumulation of mutations in the Immunoglobulin Heavy Chain (IgH) 
improve the specificity of the antigen specific B cells. Another modification process 
called Class Switch Recombination (CSR) occurs in genes located upstream of IgH 
constant region 17. Together these genetic processes (SHM and CSR) lead to affinity 
maturation and are initiated by an enzyme called cytidine deaminase 18  and cause B 
cells to differentiate into plasma cells. B cell clones that have undergone the process to 
achieve high antigen affinity and specificity are then selected by a process known as 
positive selection 19 and are retained in the GC. Altogether, the processes in the GC 
contribute to induce differentiation of B cells into mature plasma cells that secrete 
antibodies with high affinity and specificity for several foreign antigens. B cells exit 
the GC as mature plasma cells which then migrate to the bone marrow and survive there 
as long-lived plasma cells to provide for long term immunity 14,20. 
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2.2.2 Plasma Cell Dyscrasias 
Plasma cell dyscrasias (PCDs) are a mixed group of malignancies that are characterized 
by the clonal expansion of bone marrow plasma cells that secrete monoclonal Ig (M-
component) in blood serum or urine 21. The most common PCD is Multiple Myeloma 
22. PCDs begin in the germinal center after affinity maturation of B-cells and 
establishment of a clonal population of plasma B cells 23 which when uncontrolled, 
cause symptoms like lytic bone lesions and ultimately develop into B-cells neoplasms. 
On one end of the PCD disease spectrum, there is Monoclonal Gammopathy of 
Undetermined Origin (MGUS) which is relatively asymptomatic and lacks the 
symptoms of serious PCDs 24. On the other end, PCDs include intermediately severe 
condition like Smoldering Multiple Myeloma (SMM) and malignant dyscrasia like 
Solitary Plasmacytoma, Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL) 23. 
These different stages differ with respect to many components like the severity of 
symptoms, M serum protein levels, the extent of clonal expansion and concentration of 
Ig chains 24. Regardless of the different parameters of PCD stages, life-endangering 
neoplastic complications can severely harm patient survival and require immediate 
treatment measures. Amyloidosis (misfolded protein disorder where proteins with beta-
pleated sheets form fibril deposits outside the cells) 25, Crow-Fukase syndrome 26 
(complex multitude symptoms due to multiple organ failure) and Cryoglubulinemia 27 
(proteins precipitate at temperatures less than 37 degree Celsius) are few such 
complications. For this study, emphasis will be on Multiple Myeloma, a malignant and 
more symptomatic stage of PCD. 
 
2.3 Multiple Myeloma 
Multiple Myeloma (MM) is an incurable disease that first initiates in the bone marrow 
from the clonal expansion of mature antibody secreting plasma B cells 28. In this section, 
we will discuss in detail about MM, its progression, treatment, and resistance, which 
will be the basis of this study. 
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2.3.1 Epidemiology and Etiology 
Multiple Myeloma (MM) accounts for about 12-13% of all hematological neoplasms 
diagnosed every year and nearly 1% of all the diagnosed cancers 29. Annually, MM 
occurs in about 6 individuals per 100 000 people worldwide 30. It is rare in people below 
the age of 30 31, with the median age at diagnosis to be 66-70 years and is about 40% 
more common in men than women 32. Regarding ethnic distribution, there are half as 
many patients of European descent, compared to Afro-Caribbean, and there is a lower 
incidence in Asians 33.  
With the introduction of new therapeutic strategies and advanced diagnostic techniques, 
the survival rate of MM has significantly improved. Recently, it has been reported that 
the five-year survival estimate for all ages has improved to 54% from 36% between 
2001—2005 34. Average overall survival (OS) in patients less than 65 years has 
significantly increased due to new treatment approaches 35. However, despite the 
prominent improvements over the past years, MM remains an incurable disease.  
The etiology of MM is not very well understood. Increasing age, male sex, African 
ethnicity, and history of Monoclonal Gammopathy of Undetermined Significance 
(MGUS) have been documented as one of the apparent epidemiological risk factors of 
MM 36. Data-driven findings show that MGUS or Smoldering Multiple Myeloma 
(SMM) precede MM onset. Every year almost 1% cases of MM have progressed from 
preexisting MGUS 37. Several studies conducted earlier have shown that MGUS can 
develop as early as 15 years before MM development, remaining silent and 
asymptomatic for years  38.  
Genetic history of MGUS, MM or other B-cell related malignancies in the family has 
been known to cause MM. According to some studies, there is almost a 2 to 3-fold risk 
of developing MM in immediate relatives of patients with MM 39. Familial risk of MM 
has been associated with seven genetic loci: 2p, 3p, 3q, 6p, 7p, 17p and 22q 40. Familial 
risk indicates a role of genetic factors being involved in contributing to the etiology of 
MM. Genes involved in B-cell proliferation and survival pathways and apoptotic 
pathways are important genetic risk factors 39. Apart from these, occupational and 
environmental exposure are also known risk factors. Exposure to radiation causes DNA 
damage which can lead to Ig translocations and dysregulation aiding in MM 
progression 41. In agriculture, exposure to insecticides and pesticides can interfere with 
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metabolic pathways that are essential for normal homeostasis 42. Studies have reported 
a small positive association between farming and MM 39. Obesity also presents as a 
flexible risk for both MM and MGUS 39. Recently, two studies showed that obesity can 
be associated with a high risk of MM 43,44.  
Myeloma is also not a single disease entity 45 and its etiology can be associated with a 
wide range of occupational, lifestyle and genetic components. Although many 
association studies have been conducted, it is highly probable that many genetic factors 
and their roles in MM remain unidentified 40, thus, this research field demands more 
study cohorts to discover further such associations in MM. 
 
2.3.2 Clinical Presentation and Diagnosis 
Multiple myeloma’s clinical presentation can widely vary from asymptomatic 
(originating from MGUS), where the disease is discovered incidentally, to showing 
potentially fatal symptoms (advanced malignant MM). Usually, patients with MM 
show symptoms of prolonged pain in the bones (commonly ribs and back) and fatigue, 
sometimes fractures, intermittent infections, and radiculopathy 12. Renal insufficiency 
is caused because of monoclonal light chain precipitation in kidneys, and with 
hypercalcemia 46  is present in about 15-30% of MM patients 47. Some infrequent 
symptoms of MM include hyperviscosity syndrome, soft-tissue deposits, and blood 
loss, which present in around 10% of MM cases 48.  
The diagnostic hallmarks of MM are according to the original CRAB criteria, this 
criterion summarizes the major clinical manifestations of MM – Calcium levels (C), 
renal failure (R), anemia (A), and bone lesions (B) 49. In 2014, the International 
Myeloma Working Group (IMWG) proposed an updated diagnostic definition of MM 
because, before these criteria were updated, a clinical indication of serious multiple 
organ damage was needed to diagnose MM 50. The old criterion would have prevented 
early myeloma diagnosis thus postponing therapy. The updated diagnostic standards 
include the additional identification of biomarkers associated with the development of 
CRAB symptoms in patients. Patients not showing CRAB symptoms and presenting 
with bone marrow plasma cells greater than 60%, a serum-free light chain ratio of 100 
or more, or an MRI with more than one focal lesion are diagnosed with MM according 
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to the IMWG 12,50. Differences in disease diagnostic criteria between MM, SMM and 
MGUS are described in detail in Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.3 Multiple Myeloma Disease Progression 
Multiple Myeloma originates from the neoplastic development of mature long-lived 
plasma B cells of the bone marrow. It is marked by genomic instability at many levels, 
including the deregulation of plasma cell development and incorporation of genetic 
alterations 51. The events leading to malignant plasma cell population are known to be 
initiated as early as the B cell maturation stage 51. During B cell maturation, B cells 
undergo affinity maturation with the help of two processes, somatic hypermutation and 
class-switch recombination as explained in Section 2.2.1. Activation-induced 
 
Figure 2. Diagnostic criteria for MGUS, SMM and MM 
Reproduced from Majumder, M.M. (2018)
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Deaminase (AID) required for both SHM and CSR mechanisms results in Double 
Stranded Breaks (DSBs) in the immunoglobulin loci 52. Most of these DSBs are repaired 
by the cellular environment, however, some persist and can lead to genomic 
rearrangements 53 to ultimately give rise to malignant plasma cell population. These 
genomic rearrangements cause many alterations such as chromosomal translocations, 
IgH translocation and are the main molecular hallmarks of MM, leading to the 
immortalization of myeloma initiating cells 54. These initial genetic events can result in 
development of MGUS, which is a pre-malignant condition that is found to progress to 
MM in most cases 37. Along with these primary events during B cell maturation, once 
the myeloma propagating cells reach the bone marrow, the microenvironment plays a 
very important role in supporting their growth and development 53, 55. While the primary 
events like, translocations, hyperdiploidy and mistakes in DNA break repairs occur 
early and are responsible for the progression from healthy post-germinal center B cells 
to malignant plasma cell populations, the secondary genetic events including copy 
number variations, Loss of Heterozygosity (LOH), mutations acquired in the BM 
microenvironment and epigenetic factors, occur later and assist in the clonal evolution 
of MGUS to MM to Plasma Cell Leukemia  (PCL) 12. PCL is at the end of the disease 
spectrum when malignant plasma cells no longer need the BM microenvironment and 
can independently proliferate outside the BM in the blood stream 56. Figure 3 is a 
schematic representation of disease initiation to MM disease progression. The 
progression of the disease from premalignant conditions to the severe malignant disease 
involves complex clonal evolution, cumulative genetic abrasions, and epigenetic 
changes. As the disease progresses, there is a constant selection of the best clone to 
survive independently and the clones existing before them are replaced with more 
aggressive ones, thereby establishing a progressive disease and treatment resistance 57.  
 
2.3.4 Genetic Environment and Clonal Evolution 
Multiple Myeloma’s genomic landscape is quite complex and incorporates many 
genetic aberrations. There are two major subtypes of MM, based on genetic alterations, 
(1) Hyperdiploid MM (H-MM) and (2) Non- Hyperdiploid MM (NH-MM) 58. The H-
MM variant is described by the multiple trisomies mainly effecting odd chromosomes 
3, 5, 7, 9, 11, 15, 19 and 21 59. This is known to provide a favorable environment for 
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the expansion of malignant clones. On the other hand, NH-MM characteristically 
includes IgH translocations that are largely missing in H-MM 60. While H-MM is  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
known to occur early in plasma cell clonal expansion, NH-MM translocations are 
seminal incidents in disease progression 39. However, both these genetic events are 
considered as early alterations in MGUS and are not known to independently carry the 
transformation into MM. Genetic aberrations in MM include somatic mutations, copy 
number variations (CNV), chromosomal translocations and mutations that alter major 
pathways in the BM microenvironment 53.  
In the germinal center of the lymph node, during gene editing sometimes the DNA 
breaks are incorrectly joined which is when the NH-MM translocations take place 61. 
These translocations result in the juxtaposition of the IgH with an oncogene 61. This 
process locates the translocated product under a strong IgH enhancer leading to 
Figure 3. MM disease progression from naïve B cell to malignant plasma cells to Plasma 
Cell Leukemia (PCL). 
 
Representation inspired from  Bianchi, G., & Anderson, K.C. (2014)
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overexpression of the oncogene 62. The most commonly occurring translocations in 
multiple myeloma are t(11;14), t(14;16), t(4;14), t(14;20) and t(6;14) 63. These 
translocations are generated by CSR and place several oncogenes like CCND1, FGFR3 
and MMSET in control of strong enhancers 64. These are considered primary 
chromosomal events, while secondary events including deletion of 13q and 17p, as well 
as gain of 1q 65 are assumed to be acquired during the progression of MM and not 
initiating events.  
As the disease progresses, there is an increase in the burden of mutation and genetic 
complexity, which drives the disease evolution 40. In the past half-decade, due to 
cheaper and more feasible next generation sequencing technologies, vast numbers of 
recurrently mutated genes in multiple myeloma have been identified 12. Almost about 
half of MM patients harbor mutations in genes from the Mitogen Activated Protein 
Kinase pathway (MAPK), that include driver genes like BRAF, KRAS and NRAS 66, 67. 
Mutations in these genes, causes them to dysregulate cellular mechanisms like cellular 
proliferation, repair mechanisms, etc. A study conducted in approximately 450 
myeloma patients further identified a long list of mutated genes including FAM46C, 
DIS3, CYLD, TRAF3 and IFR4 67. Members of Wnt signaling pathways, adhesion 
factors like VLA4, cytokines (IL-6, BAFF, TNFα,) 68 and chemokine receptors like 
CXCR4 are known factors in creating a suitable environment in the BM for malignant 
myeloma cells 69,70. Various genes involved in the upregulation of NF-κB signaling play 
an important role in MM disease progression 71.  
When compared to other hematologic malignancies, the mutation rate in MM is higher, 
however, it is lower than most of the solid tumors 72. This favors the progression of 
malignant plasma cells and makes this disease even more aggressive. Additionally, MM 
is believed to follow Darwinian evolution led by competing clones 73, resulting in the 
best surviving clone to further expand. These sub-clones change in size and distribution 
across the course of disease based on which clone survives the best at which stage 73. 
Studies conducted in MM patients demonstrate that the progression of sub-clones 
follows different patterns and can vary from individual to individual 73. It has also been 
demonstrated that the number of clones changes with disease stage and treatments 74. 
The complexity in the clonal evolution of MM makes it difficult for one treatment 
strategy to give favorable outcomes in all patients. This is the main motivation behind 
this project, as we attempt to identify differences in gene expression profiles and 
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cytogenetic alterations of MM patients resistant or sensitive to specific treatments. 
 
2.3.5 Staging and Prognostic Factors 
Altogether, three staging systems have been proposed for multiple myeloma so far: 
Durie Salmon System (DSS), International Staging System (ISS) and the Revised 
International Staging System (RISS) 75. In the 1970s, the Durie Salmon system was 
implemented that used parameters like calcium, renal function, hemoglobin, and bone 
lesions to quantify the tumor burden in myeloma 76. To develop more clinically 
sensitive yet simple staging criteria, the IMWG in 2003, proposed the ISS system that 
included PET/CT and MRI but excluded hemoglobin assessment 12. The ISS system 
stratifies patients into three stages based on their serum albumin and serum β2-
microglobulin 77. It also predicted the overall survival in months corresponding to the 
three stages. A need for updated criteria arose because neither of the existing systems 
included chromosomal information in risk stratification. Therefore, in 2015, the ISS 
was revised to establish the RISS system 78 which classified based on existing ISS along 
with chromosomal aberrations. RISS stage I includes the patients in ISS stage I along 
with having chromosomal alterations not associated with high risk, like, 17p deletion 
or t(4;14) and having normal Lactate Dehydrogenase (LDH) levels. Stage III has 
patients with ISS stage III, high LDH and high risk associated chromosomal aberrations 
like t(11;14). Patients that fall neither in stage I nor stage III belong to stage II 79. 
Additionally, these stratification systems also hold prognostic value for MM 
progression. Presence of del(17p), t(4;14) and t(14;16) detected by fluorescence in-situ 
hybridization (FISH) is associated with poor prognosis in patients and they are stratified 
as high-risk individuals 12. Table 1 shows a detailed classification of the three systems.  
 Prognostic factors related to MM progression were determined considering either the 
patient characteristics or tumor characteristics 75. Patient-related prognostic factors 
shape the intensity of the treatment burden given to them while tumor-related factors 
indicate the tumor burden and disease progression 75. Impaired kidney function 
indicated by serum creatinine level above 2mg/dL is a poor prognostic parameter 
concerning patient characteristics and elevated LDH is a poor prognostic factor 
indicating high disease burden 75. 
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2.3.6 Treatment Terrain 
Recent years have seen advancement in multiple myeloma therapy and even though it 
remains an incurable disease, the discovery of novel therapeutic strategies has improved 
the overall survival (OS) of patients 80. Introduction of proteasome inhibitors like 
bortezomib and immunomodulatory drugs like lenalidomide have drastically changed 
the survival landscape of multiple myeloma 80. Increased myeloma disease relapse led 
to the development of second-line proteasome inhibitors like carfilzomib that have 
proved to be highly beneficial for patients in the refractory phase 12. Clinical trials have 
shown the effects of other therapies like histone deacetylase (HDAC) inhibitors, 
alkylating agents, and monoclonal antibodies, to be fruitful in improving patient 
outcome 81.  
Stage Durie-Salmon System (DSS) International 
Staging System 
(ISS) 
Revised International 
Staging System (RISS) 
I Hemoglobin >10 g/dL, serum 
calcium ≤12 mg/dL, absence of 
bone disease or solitary 
plasmacytoma, M protein <5 g/dL 
if IgG or <3 g/dL if IgA, and/or 
Bence‐Jones proteinuria <4 g/24 h 
Serum β2‐
microglobulin <3.5 
mg/dL AND serum 
albumin ≥3.5 g/dL 
ISS stage I and standard-risk 
chromosomal aberrations by 
iFISH and normal LDH 
II Meets criteria for neither stage I nor 
stage III 
Meets criteria for 
neither stage I nor 
stage III 
Not RISS stage I or III 
III One or more of the following must 
be present:  
 
Hemoglobin <8.5 g/dL, serum 
calcium >12 mg/dL, extensive bone 
lesions, M protein >7 g/dL if IgG 
and >5 g/dL if IgA; and/or Bence‐
Jones proteinuria >12 g/24 h 
Serum β2‐
microglobulin ≥5.5 
mg/dL 
ISS stage III and either high-
risk chromosomal aberrations 
by iFISH or high LDH 
 Table 1. Risk stratification of MM based on three staging systems, Durie Salmon System (DSS), 
International Staging System (ISS) and Revised International Staging System (RISS).  
Adapted from Bianchi, G., & Anderson, K.C. (2014) and Majumder, M.M. (2018) 
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There has been a dramatic increase in the number of MM therapies, however, due to 
clonal heterogeneity observed in myeloma patients, sensitive cells may be eradicated 
but resistant subclones survive and thrive under suboptimal treatment 82. Therefore, as 
much as determining the right treatment is important, deciding the synergistic drug 
combinations that can target even the resistant subclones so that relapsed cases can be 
reduced, is even more important. Further in this section, we discuss the mechanism of 
action of various treatments used in MM and detailed discussion of bortezomib and 
venetoclax which were used in this study. 
Proteasome Inhibitors (PIs): PIs are the backbone of multiple myeloma treatment, and 
are effective as both first line and refractory therapy 12. Both newly diagnosed multiple 
myeloma (NDMM) and relapsed or refractory multiple myeloma (RRMM) patients 
have shown improved overall survival with PI treatment 83. The main principle behind 
PI mechanism of action lies in increasing the misfolded/unchecked protein stress in the 
malignant cellular environment to dysregulate mechanisms so that cell is forced to 
undergo apoptosis. Proteasome degradation pathway is responsible for maintaining 
cellular homeostasis by degrading misfolded/unfolded proteins thereby regulating 
cellular proliferation, apoptosis, repair mechanisms, etc. 83 Three enzymes involved in 
polyubiquitination of the target protein, label it so that it can be detected and degraded 
by the proteasome. About 60% of cellular protein 84  is degraded by 26S proteasome 
consisting of 20S proteolytic unit and 19S regulatory unit. Once the ubiquitinated 
proteins are degraded by the 20S unit, cellular homeostasis is maintained. PIs inhibit 
this mechanism and increase cellular stress due to accumulation of proteins thereby 
inducing cell death 85. It has been investigated that PIs are more effective on malignant 
cells as compared to normal cells because malignant cells have a high requirement for 
proteins to keep up with proliferation 83. Bortezomib, carfilzomib and ixazomib are 
currently approved medications as PIs, whereas oprozomib and marizomib are still 
under clinical investigation for determining their efficacy and safety 12. Use of PIs in 
combination with immunomodulatory drugs like lenalidomide enhances overall 
response rate (ORR) of patients 12. 
Immunomodulatory drugs (IMiDs): This class of drugs include lenalidomide, 
thalidomide and pomalidomide and have significantly improved the patient outcome in 
the clinical setting 86. Like PIs, IMiDs have shown to be effective in both NDMM and 
RRMM patients including both transplant eligible and ineligible patients 12. IMiDs are 
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known to have many actions including, anti-inflammatory, anti-angiogenic, cytotoxic 
and immunomodulatory, nevertheless, recently their role has also been demonstrated in 
ubiquitination for proteasomal degradation 87. This action has been investigated and 
effects by targeting Cereblon (CRBN), which is a protein receptor for 
E3 ubiquitin ligase complex. The ubiquitination of important transcription factors, 
IKZF3 and IKZF1, is commenced once IMiDs bind to CRBN thus, leading to their 
proteasomal degradation 88. This degradation results in the reduction of IRF4 and cMYC 
that are associated with MM disease progression 88. However, for IMiDs to work 
through this mechanism, CRBN must be expressed in MM patients; downregulation of 
which could lead to a resistant mechanism to the drugs 89.  
Histone Deacetylase Inhibitors (HDACIs): Gene expression can be regulated without 
physically altering the genetic sequence, by post-translational modification in histone 
proteins 90. Histones are proteins that help package large DNA into compact form in a 
cell. Histone tails can be modified by various processes like, acetylation, methylation, 
phosphorylation, etc. thereby leading to modulation of gene expression 91. Histone 
lysine residue acetylation is regulated by two enzymes, one of them being Histone 
Deacetylase 91. HDAC led deacetylation leads to a more compact conformation of 
DNA, thereby causing transcriptional repression 91. Overexpression of HDAC causing 
hypoacetylation of histones is associated with poor prognosis not only in multiple 
myeloma, but many other cancers (e.g. colorectal, gastric, and pancreatic) 92. Thus, 
HDACIs have great potential in cancer treatments. HDACIs initiate cell cycle arrest at 
G1 phase by upregulating CDKN inhibitor 91. BCL2 family proteins which are 
proapoptotic are known to be upregulated when HDAC is inhibited resulting in 
apoptosis 93. Studies have shown that HDACIs also interfere in stress responses and 
DNA damage responses by inducing double stranded breaks 91.  These drugs also inhibit 
heat shock proteins Hsp90 which is essential for the assemble of proteins involved in 
major cancer signaling pathways like Akt, ERK, Raf, etc 91. Vorinostat is an HDACI 
that targets class I and class II HDACs, whereas panobinostat has shown about 10 times 
more inhibitory action against class I, II and IV HDACs 91. Romidepsin, a class I 
specific HDACI, was approved by the FDA in 2006 and is effective for relapsed MM 
patients 91.  
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In this study, we investigate the response to two drugs, bortezomib and venetoclax. 
While bortezomib is a conventional treatment measure administered to almost every 
myeloma patient, venetoclax has not yet been approved for MM but has shown good 
potential in clinical trials. The following sections discuss them in detail. 
 
Bortezomib: Conventional Therapy 
 In 2004, bortezomib (Bz) was the first in class boronic acid-based proteasome inhibitor 
approved by the FDA for first line of treatment in Multiple Myeloma. It is a reversible 
inhibitor of subunit β1 and β5 of proteasome 26S 83. Quick start in treatment with Bz is 
beneficial for MM patients with renal insufficiency because modifying the dose is not 
required 94. Bz has an inhibitory effect on NF-kB, which is overexpressed and helps in 
the proliferation of myeloma cells. It also inhibits the production of VEGF (Vascular 
Endothelial Growth Factor), which maintains the BM microenvironment by regulating 
angiogenesis 83. Various mechanisms of actions against myeloma progression 95 make 
Bz one of the most potent anti-myeloma drugs in the landscape. However, bortezomib 
is usually given in combination with other drugs because of better outcomes. Studies 
show that patients with a combination of Bz and dexamethasone show improved 
responses without compromising with toxicities 96. Bz has shown synergistic effects 
with melphalan and prednisone 97. Frequent side effects include fever, peripheral 
neuropathy, infection, dizziness etc. Subcutaneous administration of Bz associates with 
the least adverse effects 98. 
Bz shows great results in an initial response, but most patients relapse to Bz therapy. 
Many pathways of Bz resistance have been identified, like serine synthesis pathway 
and pentose phosphate pathway 99. However, the mechanism of resistance can be more 
complex and varied based on an individual patient’s genetic profile. Thus, for this study, 
we chose to investigate the response to bortezomib.  
 
Venetoclax: Emerging Therapy 
Venetoclax was been approved by the US Food and Drug Administration (FDA) for the 
treatment of in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia 
(AML). It is a selective BCL-2 inhibitor, a protein that is crucial for the regulation of 
apoptosis 100. Apoptosis can happen via either the extrinsic death-receptor-mediator 
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pathway or the intrinsic mitochondrial pathway. BCL-2 anti-apoptotic family of 
proteins regulate apoptosis via the mitochondrial pathway, which gets activated in 
response to stress thereby resulting in loss of mitochondrial membrane potential. This 
releases cytochrome c into the cytosol, due to which the cell must undergo apoptosis 
101. Avoiding apoptosis by dysregulation of the BCL-2 family proteins is a well-known 
mechanism of disease progression in hematologic cancers 100. This makes selective 
inhibition of BCL-2 an effective treatment strategy.  
Venetoclax is a potent treatment approach with high efficacy and safety in CLL and 
AML patients 101. Nonetheless, experiments conducted on multiple myeloma cell lines 
demonstrate that the positive effect of venetoclax even in the presence of 17p deletions 
(considered high-risk MM) 102. 20% of MM patients present with overexpression of 
BCL-2,103 suggesting that venetoclax could be an effective treatment. Although 
venetoclax is not yet approved for MM, studies investigating its effectiveness in MM 
are swiftly rising 101. In this study, we chose to investigate ex vivo sensitivity of MM 
patient samples to venetoclax as a surrogate for response. 
 
2.4 Drug Resistance in Multiple Myeloma 
Relapse burden is high in MM due to the development of resistance against existing 
drugs. Concentrating on this challenging issue, many studies have been conducted to 
examine the causative factors for resistance against MM drugs (mainly 
chemotherapeutic agents). Overexpression of P-glycoprotein (P-gp) has been identified 
to interfere with multiple chemotherapeutic drugs by preventing the accumulation of 
drug molecules intracellularly, by this means causing resistance 104. Dysregulation of 
genes involved in cell-cell interactions between Bone Marrow Stromal Cells (BMSCs) 
and MM cells can lead to adhesion of malignant cells to the BM stroma, thereby causing 
cell-adhesion mediated drug resistance (CAM-DR) 104. Additionally, BMSCs play a 
role in overexpression of drug transporter genes like ABCG2 which eventually 
contribute to CAM-DR.  HIF1A and LDHA are actively involved in MM resistance 105. 
A recent study discovered the association of upregulated LDHA and HIF1A with 
refractory MM in patients that were given Bortezomib and Melphalan therapy 105. A 
member of the Ras family, RASD1, is known to play a significant role in mediating 
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resistance against dexamethasone in MM patients 104. It has also been recognized that 
CXCR4 is associated with bortezomib resistance in MM, through CAM-DR 104. 
Many factors contribute to resistance against MM drugs, mainly genetic abnormities, 
epigenetic aberrations, and disturbed histone methylation 104. All these affect genes and 
their regulation coupled with modifying various critical pathways. The most important 
take away from this section is that gene expression and regulation is central and 
therefore a precious tool that can be used towards making better treatment decisions, 
leading to better patient response. Additionally, mechanisms of resistance against 
therapeutics like PIs and immunomodulatory agents in MM are not very well 
understood yet 104, therefore requiring further focused research in this area. Thus, this 
study is addressing relevant challenges and findings from it could potentially pave the 
way for significant breakthroughs in MM disease management. 
 
2.5 Personalized Medicine 
In the early 1950s, observations of considerable variability in drug response among 
individuals initiated the discipline of pharmacogenetics 106. It is a field that studies the 
genetic and epigenetic mechanisms underlying the variability in treatment responses. 
The commercialization of this field is now a modern and stimulating topic in healthcare, 
known as Personalized Medicine (PM) 106.  PM follows the objective that treatments 
are tailored in a manner such that they are as customized as the individual’s disease 
itself. This revolutionary approach utilizes genomic and clinical information from 
patients to understand how a patient’s unique profile makes them sensitive or resistant 
to medical treatment 107. Due to its precise nature, PM not only has the potential to 
reduce disease relapse but also dampen financial and temporal burden. New drug 
discovery is a time and money consuming procedure, to which PM provides a great 
solution where existing drugs can be utilized to patients where they are most effective 
107. 
Valuable utilization of PM relies on the availability of rigid information about 
biomarkers 107. Based on the use of biomarkers to predict a patient’s response to 
treatment, patients can be stratified, and optimal therapeutic strategies can be selected. 
However, the full potential of PM has not been realized in the clinical setting due to the 
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poor understanding of clinically significant robust biomarkers 107. This calls for more 
multidisciplinary research, at both academic and industrial level, combining clinical 
research, molecular medicine, omics-technology, and bioinformatics. When a genetics-
based allocation of treatment will be a regular occurrence in oncology, PM will be 
successfully seen simply as “medicine”.  
 
2.5.1 Biomarkers for Personalized Treatment 
Biomarkers are biological factors that can be quantified accurately to indicate, a specific 
biological mechanism, disease outcomes or therapeutic responses 12. They can be of 
two types: Prognostic and Predictive and are of great importance in personalized 
medicine 108.  Prognostic biomarkers give information about the long-term outcome of 
the disease. In the clinical setting, they are mostly used for risk stratification. Predictive 
biomarkers are of significance before treatment, in determining which patients are 
likely to respond well to therapy and which are not. For example, overexpression of the 
biomarker HER-2 in breast cancer patients indicates trastuzumab as the most effective 
treatment 108.   
Establishment of advanced high-throughput technologies and Omics technology have 
made it easier to identify these molecular or genetic markers that can help in monitoring 
response to treatment. One of the most widely used method (used in this study) to 
identify genetic biomarkers is by analyzing genomic signatures using statistical 
approaches. Following this, biomarkers need to be analytically and clinically validated 
for their robustness, to be used efficiently in clinical practice 108.  
 
2.5.2 Next Generation Sequencing  
Next Generation Sequencing (NGS) represents a powerful sequencing principle based 
on “sequencing-by-synthesis”, which means that the machine directly monitors 
simultaneous integration of nucleotides during sequencing reaction 109. This technology 
can sequence millions of DNA templates parallelly, thereby increasing the sequencing 
capacity and reducing the cost remarkably. Due to the obvious benefits, NGS’s 
increased use has enormously impacted our understanding of disease genetic 
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environment and is a revolutionary technology in detecting genetic variants in an 
individual. NGS can be applied to many DNA sources like genomic DNA (DNA), 
methylated DNA (epigenomic sequencing), or complementary DNA (RNA-Seq) 109. 
RNA-Seq data, used in this study, provides sequencing of the entire transcriptome and 
reveals information about gene expressions. While NGS produces large amounts of 
data, the translational application of that information is only possible by analyzing the 
data. Thus, NGS and bioinformatic analysis go hand in hand, to make sense of the 
information from NGS to address a research question. NGS is a crucial tool in 
personalized medicine and especially beneficial in cancer, as it a genomic disease. DNA 
sequencing in tumor samples provides an effective strategy to capture a large amount 
of genomic information not only specific to that patient but also specific to the tumor 
tissue 110. Genetic data produced can be used to identify suitable therapies according to 
the genomic signatures of individual patients.  Application of NGS in a clinical setting 
may enormously benefit medical practice through accurate identification of disease 
biomarkers, detecting inherent disorders, and identifying genetic factors that can help 
determine response to treatment. 
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3. AIM, HYPOTHESIS AND OBJECTIVES 
 
The research question addressed by this study is whether there exists a difference 
between the gene expression profiles of patients sensitive to a drug and patients resistant 
to a drug. The drugs under study are venetoclax and bortezomib.  
Aim: To identify gene expression biomarkers that can be predictive of venetoclax and 
bortezomib drug response in Multiple Myeloma.  
Hypothesis: The sensitivity to bortezomib and venetoclax is influenced by the 
expression of certain gene biomarkers. Utilizing the genomic (RNA-Seq), clinical and 
drug sensitivity and resistance testing (DSRT) data extracted from the MM patient 
samples, biomarkers associated with the venetoclax and bortezomib drug resistance can 
be predicted.  
Objectives: 
1. To group MM patient samples in ‘resistant’ and ‘sensitive’ for the bortezomib 
and venetoclax drug response using clinical and drug sensitivity and resistant 
testing (DSRT) data. 
2. To predict differentially regulated genes in ‘resistant’ and ‘sensitive’ MM 
patient samples. 
3. To identify the association of cytogenetic alterations with drug response to 
bortezomib and venetoclax. 
4. To determine the biological pathways enriched in the differentially regulated 
genes. 
The significance of this study is in its prospective application in personalized medicine. 
After experimentally validating the findings in larger cohorts, identified biomarkers can 
be used to predict suitable treatment strategies tailored for individual patients. 
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4. MATERIALS AND METHODS 
 
4.1 Patient Sample Collection 
Samples included in this study were collected from patients diagnosed with Multiple 
Myeloma. Bone marrow aspirates and peripheral blood specimens were obtained from 
patients during their standard treatment regiments. Patient samples were collected after 
informed consent and following protocols reviewed by an ethical committee of the 
Helsinki University Hospital (study permits 239/13/03/00/2010 and 
303/13/03/01/2011) and in compliance with the Declaration of Helsinki. Patients were 
anonymized by the hospital. All data generated from the samples were stored in secured 
servers at the Institute for Molecular Medicine Finland (FIMM). 
 
4.2 Drug Sensitivity and Resistance Testing (DSRT) for Venetoclax Study 
4.2.1 Venetoclax Assay Plate Preparation 
Venetoclax is a European Medicines Agency (EMA) and Food and Drug Authority (US 
FDA) approved oncology drug. For these studies, venetoclax was obtained from a 
commercial chemical vendor (ChemieTek). In compliance with the manufacturer’s 
guidelines, venetoclax was stored in desiccators prior to being dissolved in dimethyl 
sulfoxide (DMSO). An Echo acoustic liquid handler from Labcyte Inc. was used to 
transfer the drug compound in five different dilutions (ranging from 1-10,000nM), onto 
384 well plates. Storage containers pressured with nitrogen (Roylan Developments 
Ltd.) were used to store the assay ready plates of venetoclax to be used in the next step. 
4.2.2 Ex vivo Drug Sensitivity Assay 
Ex vivo drug sensitivity data for venetoclax were derived from earlier studies of the 
group 12,111. Mononuclear cells were separated from the bone marrow aspirates by Ficoll 
gradient centrifugation (GE Healthcare). CD138+ plasma cells were enriched from the 
mononuclear cell fraction by immunomagnetic bead selection (StemCell 
Technologies). Plasma cells were placed in conditioned medium from the human bone 
marrow stromal cell line HS-5 diluted to 25% with RPMI 1640 containing 10% fetal 
calf serum111 and added to the previously prepared 384 well assay plates with drugs 
23 
 
including venetoclax 111.  The plates were briefly shaken then incubated for about 72 
hours in a controlled environment at 37° C and carbon dioxide at 5%. Cell viability was 
measured after 72 hours using the CellTiter-Glo assay (Promega).  Dose-response 
curves were generated for venetoclax by feeding the luminescence intensity data 
derived from the plates to the software (Dotmatics Ltd.). According to the readout 
values, dose-response curves were fitted to quantify the venetoclax drug response on 
the patient samples in terms of Drug Sensitivity Score (DSS) for every sample, this was 
done according to previously published protocol 112. The average difference between 
the DSS scores for the cells obtained from healthy individuals and patients gave rise to 
the Selective Drug Sensitivity Score (sDSS). High sDSS indicate higher select 
sensitivity of a sample towards venetoclax, while a lower sDSS corresponds to the 
sample being more selectively resistant to venetoclax. These results are made available 
to researchers on the FIMM data warehouse, TheDB. A datasheet was created 
containing the sDSS values corresponding to each patient sample for venetoclax drug 
molecules. These samples were also sequenced (Section 4.4), and the data was stored 
in the repository. 
 
4.3 Clinical Outcome Compilation for Bortezomib Study 
Treatment regimen plans and timelines of patients with multiple myeloma from the 
Helsinki University Hospital were compiled into clinical data. This data included 
clinical outcome data of 230 patients diagnosed with multiple myeloma between 1995 
and 2019. The clinical data comprised of information on patient disease status, 
treatment, their response to the treatment, samples collected at different time points 
during their treatment, dosage information and blood parameters. Samples were 
collected from patients at different MM stages including diagnosis and relapse stages. 
These samples were then encoded, and results from further sequencing (Section 4.4) 
done on these samples were then stored in the database repository.  
 
4.4 RNA Sequencing Analysis 
Above mentioned multiple myeloma patient samples were subjected to RNA 
sequencing. RNA was extracted from CD138+ plasma cells using AllPrep® 
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DNA/RNA/miRNA Universal or miRNeasy kits (Qiagen) and then ribosomal RNA 
was separated from it using Ribo Zero rRNA Removal Kit. The libraries were generated 
by transcribing RNA to cDNA (double stranded) with the help of hexamers. RNA 
sequencing libraries were prepared using Scriptseq or Nextera technology and 
sequenced on Illumina HiSeq® 1500 or 2500 instruments (Illumina). The readout in 
terms of sequence reads was then filtered. Before proceeding with read mapping, the 
sequence reads were subjected to quality control to be filtered, trimmed, etc. These 
sequence reads were then aligned to the human genome reference (GRch38) using 
STAR aligner tool 113. Further, the read count for each gene was revealed using an 
advanced software program from the subread package called featureCount114. Figure 4 
is a schematic representation of the process from Section 4.1 to 4.6. 
 
 
 
 
 
 
 
 
 
 
 
4.5 Sample Classification for Data Analysis 
In this study, two sub-studies are investigating the effect of the drugs venetoclax and 
bortezomib. The samples were selected for each study based on the availability of RNA-
Seq data and classified based on other criteria specific to each study. The following is 
an explanation of the sample selection criteria and methodology to compile a set of data 
for each study containing sensitive and resistant samples. 
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Figure 4. Schematic representation of the study flow. 
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4.5.1 Venetoclax Drug Study 
The DSRT data containing sDSS scores of venetoclax for 200 multiple myeloma 
samples was obtained from the database, TheDB. For this study, the sample inclusion 
criteria were according to the selective Drug sensitivity scores (sDSS). Of the 200 
samples, for only 105 samples the RNA-seq data was available, thus the rest were 
excluded (Figure 5). Based on the sDSS density distribution (Figure 7), samples with 
sDSS >17.7 (top 20% samples) were considered as sensitive and samples with sDSS < 
1.97 (bottom 20% samples) were considered as resistant. With 21 resistant and 21 
sensitive samples, differential gene expression analysis for venetoclax sensitivity was 
performed. 
 
 
 
 
 
 
 
 
 
4.5.2 Bortezomib Drug Combination Study 
Among clinical data for 230 patients, 27 MM patient samples were selected for this 
study (Figure 6). These included patients’ samples which, (1) had been exposed to 
bortezomib drug combinations, and (2) had corresponding RNA-seq data. Selected 
samples (n=27) were further divided into resistant (n=12) and sensitive (n=15) samples 
based on manual stratification using the degree of clinical response to the bortezomib 
drug combination treatment. Samples from patients with “Complete Remission”, 
“Partial Remission” and “Very Good Partial Remission” consistent through multiple 
treatment sessions were considered as sensitive samples. On the other hand, patients 
with “Minimal Response”, “Progressive Disease” and “Clinical Relapse” following a 
 
DSRT Data of 200 MM Patient Samples 
Samples with RNA-Seq Data (n=105) 
Resistant to Drug Response Sensitive to Drug Response 
21 Sensitive Samples 21 Resistant Samples 
Samples without RNA-Seq Data  
sDSS < 1.97 sDSS > 17.7 
Figure 5. Sample selection in Venetoclax study. 
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few treatment sessions were considered resistant. The duration of the response degree 
also had an impact in deciding the category of that sample. With 12 resistant and 15 
sensitive samples, differential gene expression analysis was performed to predict 
biomarkers for bortezomib sensitivity in multiple myeloma. 
  
 
 
 
 
 
 
 
 
 
4.6 Differential Gene Expression Analysis 
Differential gene expression between the sensitive and resistant patients for bortezomib 
and venetoclax was identified by using the R Bioconductor115 package, DESeq2116. The 
samples were grouped into resistant and sensitive data following which the estimate 
dispersion was calculated. The list of genes, with logarithmic-2-fold change values and 
p-values indicating the significance of differential regulation, was generated. Genes 
with absolute logarithmic fold change value of greater than 1.0 and p-value of < 0.05 
were selected for further analysis.  
The raw reads for all samples in each study were normalized using the Count Per 
Million (CPM) method where mapped reads are counts scaled by the number of 
sequenced fragments multiplied by one million. Normalization across samples removes 
biases like the sequence depths of different samples during sequencing which can 
prevent the read count data from accurately reflecting the differences in expression. The 
differential read count between the two groups (resistant and sensitive) was visualized 
 Clinical Data of 230 Multiple Myeloma Patients 
Patient Treatment Data Available from Disease Diagnosis 
Patients Given Bortezomib Drug 
Combinations 
Other Drug Combinations 
Samples with 
Available RNA-Seq 
Data 
Resistant to Drug 
Response 
Sensitive to Drug 
Response 
15 Samples 
12 Samples 
Figure 6. Samples selection for Bortezomib study. 
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using heatmap.2 from the R package gplots117. All statistical analyses were performed 
using the R software environment version 3.5.2 for statistical computing and graphics. 
 
4.7 Pathway Enrichment Analysis 
The differently regulated genes for the venetoclax study generated by differential 
expression analysis were further subjected to pathway enrichment to identify their 
collective function, and to extract more knowledge about their involvement in response 
to the MM drug treatment. Pathway enrichment analysis identifies biological pathways 
enriched (more than by chance) in a gene list. The tool used in this study was, the 
Enrichr pathway analysis tool (https://amp.pharm.mssm.edu/Enrichr/)118,119 (reference 
set KEGG Human 2019). The significance of the association of each pathway to the 
gene was given by Fisher exact test p-value (<0.05). 
 
4.8 Cytogenetic Alteration Analysis 
Cytogenetics data were collected from the hematology registry (Finnish Hematology 
Registry and Biobank). These were generated using fluorescence in situ hybridization 
technology as described previously 120, following European Myeloma Network 2012 
guidelines 121. For both venetoclax and bortezomib, cytogenic alterations were analyzed 
using Chi-Squared Test to indicate a significant difference between sensitive and 
resistant samples. The alteration landscape was visualized using heatmap.2 on R. All 
statistical analysis was performed using the R software environment version 3.5.2 for 
statistical computing and graphics. 
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5. RESULTS 
 
5.1 Venetoclax Study 
5.1.1 Sample Data Characteristics 
From a group of 105 MM samples, our cohort with the most sensitive and resistant 
samples was selected. The sDSS values for all 105 samples ranged between -5.2 and 
+36.4. The bell-shaped density curve (Figure 7) shows the sDSS values distribution 
with 83.8% samples having positive sDSS values and 16.1% samples having negative 
sDSS values. To select the most resistant and sensitive samples and have the optimum 
number of samples for further analysis, 20% of all 105 samples were selected from 
extreme ends of the curve. This led to the formation of two sets of data containing 
samples that had opposite responses to venetoclax. For this study, our cohort consisted 
of 21 resistant samples with sDSS cutoff < +1.97 and 21 sensitive samples with sDSS 
> +17.7. 
 
 
 
 
 
 
 
 
 
 
5.1.2 Deriving Differential Gene Expression Based Profile for Venetoclax 
Response 
We performed differential gene expression analysis between samples resistant and 
sensitive to venetoclax drug, as explained in Section 4.6. In this study, DESeq2 
 
Figure 7. sDSS values distribution curve 
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bioconductor R package was used to determine genes that were variably expressed 
between resistant and sensitive samples sets. This is one of the most widely preferred 
tools and analyzes based on the assumption that initially, no genes are differentially 
expressed. Normalization in DESeq2 is based on geometric strategy 122.  According to 
a comparative study conducted in 2016 123, if replicate size is over 12 DESeq2 is the 
most appropriate tool for differential gene expression analysis. Following this 
approach, for both studies, DESeq2 was thought to be the best tool to obtain DEGs 
(Differentially Expressed Genes). 
Differential gene expression (DGE) analysis between 21 samples most resistant to 
venetoclax and 21 most sensitive revealed that 152 genes differed significantly (p-value 
<0.05) between the two groups. These genes were identified based on an adjusted p- 
value of < 0.05 and fold change cutoff of 1.0. Figure 8 shows the DGE analysis plot.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. DESeq2 generated differential gene expression analysis plot for venetoclax study. 
Total 152 differentially expressed (DE) genes identified plotted in red points. The remaining are 
non-DE genes plotted in gray points. Points with log2-fold> 1 change are upregulated genes 
and points with log2-fold change< -1 are downregulated genes in resistant samples. 
 
30 
 
Among these, there were only 74 protein-coding genes. Genes with fold change < -1.0 
(n=38) were downregulated genes (Table 2) in the resistant samples. Genes with fold 
change > 1.0 were upregulated genes (n=36) (Table 3) in the resistant samples. Finally, 
63 protein-coding genes were selected based on absolute fold change cutoff of 1.2 and 
adjusted p-value < 0.05, for further use in pathway enrichment analysis. 
The objective of this primary selection was to generate a list of genes that were highly 
variable between sensitive and resistant patient samples to further identify their 
significance in critical pathways of multiple myeloma. We identified a list of 
differentially regulated genes for the venetoclax study which were further analyzed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Downregulated protein coding genes (n=38) in resistant samples generated by DESeq2 
analysis for venetoclax study. 
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5.1.3 Visualizing Variability Between Gene Expressions of Venetoclax Resistant 
and Sensitive Samples 
To visualize the variations in gene expression patterns between sensitive and resistant 
samples, heatmaps were generated using heatmap.2 from the R package gplots. For 
visualization, normalized gene expression data obtained from sequencing (Section 4.4) 
was subjected to minmax linear transformation and the data was scaled between 0 and 
1. The entire range of expression values between 0 and 1 were mapped for each gene 
(selected after differential genes expression analysis in Section 5.1.2) and visualized 
among the resistant and sensitive groups. 
The protein-coding 74 genes obtained after differential gene expression (Section 5.1.2) 
were used to map their expression across all samples. The results, shown in Figure 9, 
show a clear representation of differences between the gene expressions profiles of the 
two sets (resistant and sensitive).  
 
Table 3. Upregulated protein coding genes (n=36) in resistant samples generated by DESeq2 analysis 
for venetoclax study. 
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PARM1 
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RAPGEF3 
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RIMS1 
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KCNMB2 
SMAD7 
KCNJ3 
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A. 
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PPFIBP1 
FJX1 
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PXDN 
DHRS7B 
FAH 
ARNT2 
ATP2B4 
PRRT1 
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HIST1H2BJ 
KIF14 
HOXB7 
PTPDC1 
PKIG 
NEDD4 
MSRB3 
SLAMF6 
SENSITIVE SAMPLES RESISTANT SAMPLES 
B. 
Figure 9. Heatmap visualizing gene expression profiles of 74 DE genes across sensitive and resistant 
samples from venetoclax study. (A.) Heatmap of downregulated genes (n=38) obtained from DESeq 
analysis. (B.) Heatmap of upregulated genes (n=36) obtained from DESeq analysis. The color key 
indicates gene expression between 0 (lowest expression) and 1 (highest expression). 
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This visualization indicates the presence of an association between varying expression 
profile and response to drug. Genes that are seen to be upregulated in the resistant group 
showed overall downregulation in the sensitive group, and vice versa. Further, 
expression of each of the specific 36 genes upregulated and 38 genes downregulated in 
venetoclax resistant samples can be distinctly observed. 
Visualizing the expression profiles is an integral process that assists in cross validating 
the results achieved from the differential gene expression analysis. For instance, if the 
analysis reveals a significant gene with very high log2-fold change value but in the 
heatmap its expression is seen to be less consistent across replicates, then this is an 
indication that DGE analysis generated a false positive. Therefore, visualizing the 
actual gene expression is a valuable method. It is evident that for the venetoclax study, 
the visualized gene expression profile is consistent with the analysis. 
 
5.1.4 Identifying Pathways Enriched with Differentially Expressed Genes (DEGs)  
For the venetoclax study, 63 genes (top genes with absolute fold change cutoff > 1.2) 
resulting from the differential analysis were then further analyzed using pathway 
enrichment (as explained in Section 4.7). Fisher’s exact (FE) test is used by the 
enrichment tool to measure the non-random association of the DEG list with the genes 
involved in a pathway, calculating the probability of this association. A combined score 
is finally calculated for each association which is the product of logarithm of FE test p-
value and the z-score of deviation from the rank118. The higher the combined score, the 
better the overall ranking of the pathway and the better the p-value of the enriched gene 
association.  
Genes with a |log2-fold change| > 1.2 and adjusted p-value <0.05, involving 31 
downregulated genes and 32 upregulated genes were separately analyzed to identify the 
enriched pathways these were associated with. Out of 31 downregulated genes, 8 genes 
were most significantly (p-value <0.05) enriched in 11 pathways (Table 4) and among 
32 upregulated genes, 4 genes were enriched most significantly in 5 pathways (Table 
5). CCND1, BCL2, STAT4, RELN, COL45A, are among the top hits that critically 
control the pathways highlighted by the enrichment tool. The enriched pathways in the 
results included very crucial cancer regulatory mechanisms. The functional significance 
of these genes and pathways in MM resistance is further reviewed in the Discussion. 
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5.1.5 Deriving Cytogenetic Alteration Based Profile of Venetoclax Response  
This study aimed to reveal that the incidence of chromosomal aberrations like 
translocations, deletions, chromosomal gain, etc. can significantly vary between 
patients sensitive or resistant to venetoclax treatment, thus it can present as a predictive 
factor in determining patient’s response to therapy. Chromosomal aberrations, 
translocation at loci t(4;14), t(11;14), deletion at loci del17p13, del.13q and gain at 
chr1q arm were presented in a matrix, indicating the presence or absence of these 
Term P-value Overlapping Genes 
Hippo signaling pathway 0.00345193048774113 PATJ; CCND1; SMAD7 
JAK-STAT signaling 
pathway 0.00357451390623893 CCND1; STAT4; BCL2 
Hedgehog signaling 
pathway 0.00360044473922809 CCND1; BCL2 
p53 signaling pathway 0.00826304538008702 CCND1; BCL2 
Colorectal cancer 0.01162064652592770 CCND1; BCL2 
Small cell lung cancer 0.01348869563408350 CCND1; BCL2 
Prostate cancer 0.01461095144404510 CCND1; BCL2 
AGE-RAGE signaling 
pathway in diabetic 
complications 
0.01547831322353650 CCND1; BCL2 
MicroRNAs in cancer 0.01897485449460060 CCND1; PDCD4; BCL2 
Cholinergic synapse 0.01916225418792300 BCL2; KCNJ3 
Serotonergic synapse 0.01948440848633600 RAPGEF3; KCNJ3 
 
Table 1. Pathways enriched with overlapping genes from downregulated DE gene list. 
Term P-value Overlapping Genes 
ECM-receptor interaction 0.00955781492889581  RELN; COL4A5 
Primary bile acid biosynthesis 0.03017501197648500  HSD3B7 
Other glycan degradation 0.03192217639649050  MAN2B1 
Focal adhesion 0.04975267803531580  RELN; COL4A5 
PI3K-Akt signaling pathway 0.04986949005096340  RELN; COL4A5 
 
Table 5. Pathways enriched with overlapping genes from upregulated DE gene list. 
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alterations across the sensitive and resistant venetoclax samples (Figure 10). Visually, 
the profile suggests there are variations between the alterations of resistant and 
responsive samples, therefore Pearson's Chi-squared test with Yates' continuity 
correction was performed to signify the association between the cytogenetic alterations 
and sample response to venetoclax treatment. The relations between translocation 
t(11;14) and sensitive samples was significant with X2 (df=1, N=21) = 12.317 and p-
value = 0.0004489. Patients with t(11;14) were more likely to be responsive to 
venetoclax treatment. The relations between translocation t(4;14) and resistant samples 
was significant with X2 (df=1, N=21) = 6.8234 and p-value = 0.008997. Patients with 
t(4;14) are more likely to be resistant to venetoclax treatment. Alterations del17p13, 
del.13q and gain at chr1q did not have a significant association with the treatment 
response.  
 
 
 
 
 
 
 
5.2 Bortezomib Drug Combination Study 
5.2.1 Sample Data Characteristics 
Clinical data consisting of information from 230 MM patients was used to select 
samples sensitive and resistant to bortezomib drug combinations. Patient age at 
diagnosis ranged from 26-87 years with an average age of 64 years. Selection and 
classification criteria as explained in Section 4.5.2 was followed to get 15 sensitive and 
12 resistant samples. There were 4 distinct bortezomib drug combinations provided 
(Figure 11), (1) bortezomib, dexamethasone and lenalidomide (2) bortezomib, 
cyclophosphamide, dexamethasone (3) bortezomib, melphalan, prednisone (4) 
bortezomib and dexamethasone. Average M-protein level, one of the most significant 
SENSITIVE SAMPLES RESISTANT SAMPLES 
Figure 10. Matrix visualizing cytogenetic alterations between resistant and sensitive 
samples from venetoclax study. Gray blocks indicate absence of alteration and black 
blocks indicate presence of alteration. 
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diagnostic parameters for MM, for sensitive samples was 38.3g/L and for resistant 
samples was 40.2g/L, indicating a higher M spike for samples resistant to bortezomib 
drug combinations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.2 Deriving Differential Gene Expression Based Profile for Bortezomib 
Response 
DESeq2 analysis for the bortezomib study identified 1 gene with significant differential 
gene expression between 15 highly sensitive samples and 12 highly resistant samples. 
Figure 12 shows the DGE analysis plot for Bortezomib study. With adjusted p-value 
<0.05 and fold change of -1.09, SVOP gene was identified to be downregulated in the 
resistant samples compared to sensitive ones. Since this analysis did not reveal a 
conclusive list of genes, we did not proceed with further analysis for the bortezomib 
study. Like the cytogenetic alteration analysis done in the venetoclax study, the analysis 
was performed with the resistant and sensitive samples of bortezomib study; however, 
 
Figure 11. Bar chart showing frequencies of different Bortezomib drug 
combinations given to patients. (1) BOR/DXM/LEN- Combination of 
Bortezomib, Dexamethasone and Lenalidomide given to 11 patients. (2) 
BOR/CPM/DXM- Combination of Bz, Cyclophosphamide, Dexamethasone 
given to 9 patients. (3) BOR/DXM- Bortezomib, Dexamethasone given to 5 
patients. (4) BOR/MEL/PRED- Combination of Bortezomib, Melphalan, 
Prednisone given to 2 patients. 
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it did not inform of any significant association between cytogenetic alterations and 
response to bortezomib drug combinations. Nonetheless, potential causes behind the 
unsuccessful results for this study are discussed later in Section 6.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. DESeq2 generated differential gene expression analysis plot for Bortezomib 
study. Only 1 differentially expressed (DE) downregulated gene identified is plotted in red 
point. The remaining are non-DE genes plotted in black points. 
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6. DISCUSSION 
 
6.1 Differential Gene Expression Profiling: A Translational Approach 
We used RNA-Seq data to investigate differential gene expression patterns of many 
genes between sensitive and resistant samples and identified predictive biomarkers. A 
multitude of studies have used gene signature profiling to identify prognostic markers 
for multiple myeloma, but there are not many where gene signatures are analyzed in 
response to specific drug treatments. Furthermore, most of the differential gene 
expression-based studies are done on human myeloma cell lines that do not always 
reflect the accurate genetic and phenotypic make-up of their tissue of origin nor the 
heterogeneity of the disease. Whereas using CD138+ plasma cells obtained from patient 
samples for RNA-Seq and ex vivo drug response provides precise information 
regarding the important markers and functions. The bortezomib study incorporates 
clinical profile-based drug response, which is the best representation of in vivo 
microenvironment changes.  
We successfully identified venetoclax-associated biomarkers to create a gene panel that 
can be further explored and validated. Many genes identified in our study have been 
previously associated with either disease progression or prognosis in multiple myeloma. 
By using systemic tools to explore large scale genomic data, this study is a translational 
approach to predicting drug response biomarkers and has the potential to translate into 
the clinical setting. 
 
6.2 Varying Gene Expressions Can Drive Venetoclax Resistance in MM 
The differentially regulated genes identified for venetoclax response play crucial roles 
in cancer pathways that might impart resistance to drug action. In this section, a 
literature-based previously discovered association of the genomic signatures with MM 
resistance will be discussed, with respect to the gene list discovered in our study. 
Reelin protein translated from gene RELN is an extracellular matrix (ECM) 
glycoprotein responsible for ECM-receptor interactions of neuronal cells. 
Overexpression of RELN is associated with poor progression-free survival in patients 
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with multiple myeloma 124. In 2016, a study investigated the expression of RELN in 
MM and it was found that it facilitates the adhesion of malignant cells to fibronectin 
thereby fostering resistance against drug-induced cell apoptosis 125.  In our study, RELN 
was the most significantly upregulated gene in the venetoclax resistant cohort (Table 3; 
log2-fold change :3.7; p-value: 0.03) and was also found enriched in ECM-receptor 
interaction and focal adhesion pathways (Table 5).  
MM spike genes are genes that are overexpressed in myeloma cells. A study conducted 
in 2011, identified an association between these genes and poor MM prognosis with 
decreased treatment sensitivity 126. RHOU, MSRB3, HIST1H2B, HOXB7 and COL4A5 
were some of the spike genes identified with high bad prognostic values. Remarkably, 
these genes are significantly overexpressed in our venetoclax resistant samples (Table 
3).  
Another study in 2013, identified the association of overexpressed KIF14 along with 
ABCB1 in imparting resistance against MM therapy in cell lines that were positive for 
t(4;14) 127. Our study reveals significant upregulation of KIF14 in resistant samples 
(Table 3; log2-fold change: 1.74; p-value: 0.026) that also are significantly positive for 
t(4;14) translocation (Figure 10).  
STAT family of proteins play a very crucial role in regulating cellular proliferation, 
differentiation, and apoptosis. Role of STAT3 in driving cancer metastasis is a very 
well-investigated phenomenon, though, interestingly, it did not show up in the DEG 
profile. Instead, our study shows a significant downregulation of STAT4 in resistant 
samples (Table 2; log2-fold change: -1.29; p-value: 0.005). The exact function of 
STAT4 in cancer progression is limited and not yet investigated deeply, however, some 
studies have shown the association of high STAT4 expression with good prognosis and 
treatment sensitive in gastric cancers 128, ovarian cancers 129 and liver cancers 130. It 
could be inferred that STAT4 associates with good prognosis and sensitive drug 
response in myeloma.  
Drug resistance in multiple myeloma has been associated with lower expression of the 
transient receptor potential channel (TRPC) family of genes 131. Thus, downregulation 
of TRPC3 (Table 2; log2-fold change: -2.36; p-value: 0.003) in resistant samples is a 
potential indicator of venetoclax response in MM. 
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The BCL2 gene is responsible for producing proteins that facilitate the inhibition of 
cellular apoptosis, thus are found to be upregulated in hematologic malignancies. Since 
venetoclax is a BCL2 specific inhibitor, one might speculate that a lower expression of 
BCL2 in patient will lead to a positive response to venetoclax. However, a recent study 
demonstrated that BCL2 expression effects drug response in different ways for different 
hematological malignancies 132. For multiple myeloma, lower expression of BCL2, 
BCL2L11 and BAX along with overexpression of BCL2L1 gives rise to a bad Overall 
Response Rate (ORR) to venetoclax and poor Progression Free Survival (PFS) as 
compared to CLL (for which venetoclax is the first line of treatment, approved in the 
United States) 132.  In this study, BCL2 downregulation was identified in resistant 
venetoclax samples (Table 2; log2-fold change: -1.23; p-value: 0.001), therefore a 
lower expression of BCL2 in multiple myeloma patients could be predictive of poor 
venetoclax response. 
 
6.3 Identified Pathways are Associated with Drug Resistance in MM 
In pathway enrichment analysis, several important pathways were enriched with genes 
like BCL2, CCND1, SMAD7, etc. (Table 4 and Table 5). Deregulation of the genes 
involved in these pathways may lead to acquired resistance against treatment.   
The bone marrow microenvironment can impart resistance to myeloma therapy mainly 
through two mechanisms, (1) cell adhesion mediated interaction of the malignant cells 
with fibronectin and (2) inhibition of apoptosis due to cytokine driven actions, which 
involve both JAK/STAT pathway and PI3K/AKT signaling 133. In our study, important 
genes RELN and COL2A4 were found upregulated in resistant samples. These genes 
were enriched in pathways (Table 5), ECM-receptor interaction, focal adhesion and 
PI3K/AKT signaling, which are involved in supporting survival of malignant myeloma 
cells 133, thereby leading to progression of resistant disease. 
Hedgehog pathway and genetic factors involved in this pathway play a major role in 
modulating the stem cell environment in MM 134. Abnormal activation of hedgehog 
signaling is promoted by deregulation of factors like BCL2 and causes clonal expansion 
in MM 133. Results from our study are consistent with the involvement of hedgehog 
pathway in MM disease progression (Table 4). 
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Pathway enrichment in this study identified p53 pathway enriched with downregulated 
genes in resistant samples (Table 4). Attenuation of p53 pathway is associated with 
tumorigenesis and confers resistance to treatment not in MM but many cancers 135. 
Hippo signaling (Table 4) plays a crucial part in apoptosis of lymphocytes and are 
therefore very important in MM progression 136. Their downregulation is associated 
with aggressive cancer development and signaling is linked with TGFβ pathway 
involving the SMAD family of proteins 136136. 
 
6.4 CCND1 Expression and Chromosomal Translocations Predict 
Response to Venetoclax in MM 
The CCND1 gene expresses Cyclin D1, a protein that causes the release of E2F, a 
transcription factor, through phosphorylation of retinoblastoma 137. This process leads 
to the transition of cell cycle from G1 to synthesis phase resulting in cellular 
proliferation and DNA replication. Deregulation of CCND1 is usually the case in most 
malignancies, but it is most common in Multiple Myeloma 137. Overexpression of 
CCND1 gene occurs due to a translocation alteration t(11;14) 63. Patients with t(11;14) 
have high levels of Cyclin D protein. t(11;14) and CCND1 overexpression has been 
shown to predict venetoclax drug response in multiple myeloma 138. Translocation 
t(11;14) is one of the most common alterations in myeloma patients and occurs early in 
disease development causing the upregulation of CCND1. Previous studies have 
demonstrated that presence of t(11;14) and overexpressed CCND1 has been associated 
with positive drug response in myeloma 12 and in our study, venetoclax resistance does 
correspond with downregulated CCND1 expression (Table 2; log2-fold change: -4.16; 
p-value: 0.0005). Moreover, patients with t(11;14) were more likely to be responsive 
to venetoclax treatment (p-value = 0.0004)  in our sensitive cohort.  
Translocation t(4;14) occurs in about 10%-25% of myeloma patients and translocation 
of genes into this location leads to their overexpression 139. It is usually associated with 
overexpression of FGRF3 and MMSET domain that promotes myeloma disease 
progression. t(4;14) is known to be associated with resistance against venetoclax 
12Error! Bookmark not defined.. In our study, resistant samples have a significantly 
higher number of t(4;14) as compared to sensitive samples (p-value: 0.008; Figure 10). 
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Therefore, our study identified t(4;14) as a biomarker for resistance to venetoclax in 
MM and CCND1 and t(11;14) as indicators of sensitivity. 
 
6.5 Limitations of Bortezomib Drug Combination Study  
Only 1 differentially regulated gene was obtained for the bortezomib study and the 
results from the cytogenetic analysis were not conclusive, unlike the venetoclax study. 
One reason for this could be the small cohort size (n=27) of the bortezomib study as 
compared to the venetoclax study (n=42). The samples were characterized (into 
resistant and sensitive) based on the clinical response of patients to bortezomib. 
However, during treatment administration, patients were given 4 different drugs in 
combination with bortezomib (refer to Section 5.2.1) instead of just solely being 
administered with bortezomib (as was the case with the venetoclax study). Moreover, 
patients also received other medications for controlling side effects or for some other 
conditions that were not considered in this study. When there are so many 
pharmacological factors involved, cascades of changes happen in the 
microenvironment which ultimately affects the gene expression patterns. This could be 
a reason for the poor result from differential gene expression analysis of samples from 
patients administered with bortezomib drug combinations.  
In order to get more clarity on this, we did a small graphical correlation between clinical 
response-based profiling of patients (into resistant and sensitive) administered with 
bortezomib drug combination and sDSS bortezomib score-based profiling of samples 
from the same patients.  Figure 13 shows that samples deemed resistant based on 
clinical outcome of bortezomib drug combinations were not resistant based on the sDSS 
scores of bortezomib ex vivo study.  
This shows a lack of correlation between clinical and ex vivo studies for bortezomib. 
While further exploration into this was out of the scope of this study, investigating the 
differences between clinical and ex vivo studies would be a valuable experiment which 
can improve the application of ex vivo drug testing in the clinical setting. 
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6.6 Conclusion and Future Prospects    
Despite the development of therapeutic strategies, multiple myeloma remains an 
incurable disease with a standing issue of ultimately relapsing in initially responsive 
patients. This study aimed to tackle that problem by developing a methodology to 
predict patient response to drugs. In this study we identified 74 protein-coding gene 
biomarkers of venetoclax resistance in MM, and 2 cytogenetic alterations associated 
with venetoclax resistance. This demonstrates that comparative study of gene 
expression signatures and cytogenetic alterations can indicate patient response to a 
specific treatment. Our primary goal was to identify predictive biomarkers for drug 
response; however, this is only an elementary step that needs further validation and 
verification. The over/under-expression of the identified genes can be verified by 
quantitative PCR analysis of the patient samples. Further investigation into exploring 
the pathways through which the identified genes function, will give: (1) insight into 
resistance acquiring mechanisms and (2) novel drug targets for resistant multiple 
myeloma. A similar analysis could be done for a larger sample size and for a wider 
range of data (like proteomics data), which would enhance the translational impact in 
clinical settings. The results from this study provide a basis for the development of 
further research that is guided by patient’s genomic landscape, verified in large cohorts, 
applicable in the clinical setting and results in personalized targeted treatment 
strategies. This study is a small contribution towards realizing the goal of personalized 
medicine eventually becoming the norm. 
Figure 13. A bar chart showing the correlation between clinical response-
based profiling of patients (into resistant and sensitive) and sDSS score-based 
profiling of samples from the same patients. Positive sDSS value indicates 
sensitive response and negative sDSS indicates resistant response.  
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